M&A Deal Summary

H.I.G. Private Equity Acquires BioVectra

On September 10, 2019, private equity firm H.I.G. Private Equity acquired life science company BioVectra from Questcor Pharmaceuticals for 250M USD

Acquisition Highlights
  • This is H.I.G. Private Equity’s 3rd transaction in the Life Science sector.
  • This is H.I.G. Private Equity’s 11th largest (disclosed) transaction.
  • This is H.I.G. Private Equity’s 12th transaction in Canada.
  • This is H.I.G. Private Equity’s 1st transaction in Prince Edward Island.

M&A Deal Summary

Date 2019-09-10
Target BioVectra
Sector Life Science
Buyer(s) H.I.G. Private Equity
Sellers(s) Questcor Pharmaceuticals
Deal Type Divestiture
Deal Value 250M USD

Target

BioVectra

Charlottetown, Prince Edward Island, Canada
website
BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

H.I.G. Private Equity

Miami, Florida, United States

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 1993
PE ASSETS 57.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

HIG Private Equity is the private equity arm of HIG Capital LLC. The firm focuses on management buyouts, growth equity investments, and recapitalizations of middle market companies with an enterprise value of $50 - $500 million. The Firm also will consider add-on acquisitions, industry consolidations, going-privates, and corporate divestitures. Sectors of interest include aerospace, building materials, business services, consumer products, distribution, healthcare, infrastructure, contracting, manufacturing, media, oil & gas services, IT, and transportation. HIG was formed in 1993 and has offices in Miami, Atlanta, Boston, and San Francisco. HIG's European affiliate is HIG Europe with offices in London, Hamburg, and Paris.


DEAL STATS #
Overall 252 of 349
Sector (Life Science) 3 of 5
Type (Divestiture) 30 of 44
State (Prince Edward Island) 1 of 1
Country (Canada) 12 of 14
Year (2019) 15 of 18
Size (of disclosed) 11 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-04 Nadir Figueiredo

São Paulo, Brazil

Nadir Figueiredo is a glass tableware producer in Brazil and the 6th largest in the world. Nadir Figueiredo Indústria e Comércio S.A. built a 107-year success story in Brazil as a result of its high-quality products and long-standing relationships with all major distributors and retailers. Nadir can be found in nearly every household across all Brazilian states.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-24 RxStrategies

Boca Raton, Florida, United States

RxStrategies, Inc. provides the federally qualified community health centers (FQHC), other qualified entities and the pharmacy partners with a full turn-key solution for the implementation and on-going management of the 340B discount prescription drug program. RxStrategies was founded in 2003 and is based in Boca Raton, Florida.

Sell -

Seller(S) 1

SELLER

Questcor Pharmaceuticals

Anaheim, California, United States

website


Category Company
Founded 1990
Sector Life Science
DESCRIPTION

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company that provides drugs for the treatment of autoimmune and inflammatory disorders.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Prince Edward Island) 1 of 1
Country (Canada) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-11 Rights to Synacthen

United States

Synacthen® and Synacthen Depot® in certain countries outside the U.S. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for certain autoimmune and inflammatory conditions, but have never been developed or approved for patients in the U.S.

Buy $60M